Advertisement
U.S. markets open in 4 hours 36 minutes

Leap Therapeutics, Inc. (LPTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7800+0.3000 (+12.10%)
At close: 04:00PM EDT
2.8497 +0.07 (+2.51%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close2.4800
Open2.5000
Bid2.7400 x 100
Ask2.8400 x 100
Day's Range2.4400 - 2.8099
52 Week Range1.2350 - 10.2000
Volume191,694
Avg. Volume243,065
Market Cap71.168M
Beta (5Y Monthly)0.59
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for LPTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Leap Therapeutics, Inc.
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID) have underperformed large-caps over the past 12 months, but may be in a better position to generate market-beating returns going forward. SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from global events. As well, the prices of SMID stocks generally are lower than the prices of large-caps. As well, there are long stretches in the record books when SMID stocks have outperformed large-caps. That said, SMID stocks can be risky. The standard deviation for monthly returns was 5.7% for SMID stocks over a 2003-2021 test period, versus 4.3% for large-caps. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Zacks

    Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks

    Leap Therapeutics (LPTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

  • TipRanks

    These 2 “Strong Buy” Penny Stocks Could Gain Over 500%, Says Baird

    In the classic tune by Kenny Rogers, ‘The Gambler,’ he sang, ‘Every hand’s a winner and every hand’s a loser…’ These words hold valuable wisdom that should resonate with every investor. Regardless of your chosen investment strategy, achieving success in the stock market ultimately hinges on mastering the art of balancing risk and reward. Few segments of the stock market offer a higher potential return for the risk involved than the penny stocks, those equities priced at $5 or less. These are sto

  • Insider Monkey

    10 Most Promising Penny Stocks According to Analysts

    In this article, we will take a look at the 10 most promising penny stocks according to analysts. To see more such companies, go directly to 5 Most Promising Penny Stocks According to Analysts. Innovation is what drives human societies forward. Major companies of today were once small companies working on innovative and disruptive ideas. […]